Epizyme, Inc. clinical trials

Acquired by Ipsen, Aug 12, 2022 · source ↗

The registry lists 21 studies whose lead sponsor is Epizyme, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 5, 2026.

Studies

Recruiting first, then most recently updated. Showing 21 of 21. All Ipsen studies →

• A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.Active, not recruitingNCT04224493Phase 3

  Sponsor listed in the registry: Epizyme, Inc. · First submitted before Epizyme, Inc. became part of Ipsen

• Tazemetostat Expanded Access Program for Adults With Epithelioid SarcomaNo longer availableNCT04225429

  Sponsor listed in the registry: Epizyme, Inc. · First submitted before Epizyme, Inc. became part of Ipsen

• Tazemetostat Expanded Access Program for Adults With Solid TumorsNo longer availableNCT03874455

  Sponsor listed in the registry: Epizyme, Inc. · First submitted before Epizyme, Inc. became part of Ipsen

• A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver FunctionTerminatedNCT04241835Phase 1

  Sponsor listed in the registry: Epizyme, Inc. · First submitted before Epizyme, Inc. became part of Ipsen

• A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate CancerTerminatedNCT04179864Phase 1/2

  Sponsor listed in the registry: Epizyme, Inc. · First submitted before Epizyme, Inc. became part of Ipsen

• A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic MutationWithdrawnNCT06068881Phase 2

  Sponsor listed in the registry: Epizyme, Inc. · First submitted after Epizyme, Inc. became part of Ipsen

• Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid SarcomaTerminatedNCT04204941Phase 1

  Sponsor listed in the registry: Epizyme, Inc. · First submitted before Epizyme, Inc. became part of Ipsen

• A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical StudyCompletedNCT02875548Phase 1/2

  Sponsor listed in the registry: Epizyme, Inc. · First submitted before Epizyme, Inc. became part of Ipsen

• A Study of Tazemetostat in Adult Participants With Soft Tissue SarcomaCompletedNCT02601950Phase 2

  Sponsor listed in the registry: Epizyme, Inc. · First submitted before Epizyme, Inc. became part of Ipsen

• A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell LymphomaTerminatedNCT05121103Phase 1

  Sponsor listed in the registry: Epizyme, Inc. · First submitted before Epizyme, Inc. became part of Ipsen

• Effects of Itraconazole and Rifampin on the Blood Tazemetostat LevelsCompletedNCT04537715Phase 1

  Sponsor listed in the registry: Epizyme, Inc. · First submitted before Epizyme, Inc. became part of Ipsen

• EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial SarcomaCompletedNCT02601937Phase 1

  Sponsor listed in the registry: Epizyme, Inc. · First submitted before Epizyme, Inc. became part of Ipsen

• A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias InvolvingCompletedNCT01684150Phase 1

  Sponsor listed in the registry: Epizyme, Inc. · First submitted before Epizyme, Inc. became part of Ipsen

• Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCLCompletedNCT01897571Phase 1/2

  Sponsor listed in the registry: Epizyme, Inc. · First submitted before Epizyme, Inc. became part of Ipsen

• SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular LymphomaTerminatedNCT04762160Phase 2

  Sponsor listed in the registry: Epizyme, Inc. · First submitted before Epizyme, Inc. became part of Ipsen

• Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid TumorsCompletedNCT03010982Phase 1

  Sponsor listed in the registry: Epizyme, Inc. · First submitted before Epizyme, Inc. became part of Ipsen

• Epithelioid Sarcoma Natural History StudyCompletedNCT03837678

  Sponsor listed in the registry: Epizyme, Inc. · First submitted before Epizyme, Inc. became part of Ipsen

• A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.WithdrawnNCT05205252Phase 1/2

  Sponsor listed in the registry: Epizyme, Inc. · First submitted before Epizyme, Inc. became part of Ipsen

• Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor PatientsCompletedNCT03028103Phase 1

  Sponsor listed in the registry: Epizyme, Inc. · First submitted before Epizyme, Inc. became part of Ipsen

• A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL GeneCompletedNCT02141828Phase 1

  Sponsor listed in the registry: Epizyme, Inc. · First submitted before Epizyme, Inc. became part of Ipsen

• Study of the EZH2 Inhibitor Tazemetostat in Malignant MesotheliomaCompletedNCT02860286Phase 2

  Sponsor listed in the registry: Epizyme, Inc. · First submitted before Epizyme, Inc. became part of Ipsen